Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference
GRAND CAYMAN, CAYMAN ISLANDS, Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that the Company’s management will be attending and presenting at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference taking place December 3-4, 2024, in Boca Raton, Florida.
Ilan Hadar, Chief Executive Officer will deliver a company presentation titled “Transforming Cancer Care: Silexion Therapeutics’ Innovative Approach to Pancreatic Cancer” on December 4, 2024 at 11:30 am. A replay of the presentation will be posted, when available, to Silexion’s website on the Presentation & Events page of the investors section.
The Company’s management team will be available for one-on-one meetings throughout the summit. Interested investors are encouraged to contact the Noble investor outreach team to schedule a meeting.
About Silexion Therapuetics
Silexion Therapeutics (NASDAQ: SLXN) is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations, the most common oncogenic driver in human cancers. The company's first-generation product, LODER™, has shown promising results in a Phase 2 trial for non-resectable pancreatic cancer. Silexion is also advancing its next-generation siRNA candidate, SIL-204, designed to target a broader range of KRAS mutations and showing significant potential in preclinical studies. The company remains committed to pushing the boundaries of therapeutic innovation in oncology, with a focus on improving outcomes for patients with difficult-to-treat cancers. For more information please visit: https://silexion.com
Company Contact
Silexion Therapeutics Corp
Ms. Mirit Horenshtein Hadar, CFO
mirit@silexion.com
Investor Contact
ARX | Capital Markets Advisors
North American Equities Desk
silexion@arxadvisory.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
